S. Ma

The significance of LMO2 expression in the progression of prostate cancer

X. Guan, K. Y. Wong, Stephanie Ma, 2007, The Journal of pathology.

SKLB-287, a novel oral multikinase inhibitor of EGFR and VEGFR2, exhibits potent antitumor activity in LoVo colorectal tumor model.

L. Zhong, Mingwu Zheng, S. Ma, 2014, Neoplasma.

SKLB1028, a novel oral multikinase inhibitor of EGFR, FLT3 and Abl, displays exceptional activity in models of FLT3-driven AML and considerable potency in models of CML harboring Abl mutants

L. Zhong, R. Zheng, Z. Cao, 2012, Leukemia.

The rat Nb2 lymphoma: a novel model for tumor progression.

D. Horsman, N. Bruchovsky, P. Gout, 1994, Anticancer research.

CD133+ HCC cancer stem cells confer chemoresistance by preferential expression of the Akt/PKB survival pathway

X. Guan, B. Zheng, K. Chan, 2008, Oncogene.

Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors

B. Rubin, A. Pobbati, Anu Gupta, 2021, PloS one.

Correlation between p53 and epidermal growth factor receptor expression in breast cancer classification.

D. Mu, W. Zuo, Q. Liu, 2015, Genetics and molecular research : GMR.